The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.

@article{Heckman2008TheTK,
  title={The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.},
  author={Caroline A Heckman and Tanja Holopainen and Maria Wirzenius and Salla Keskitalo and Michael Jeltsch and Seppo Yl{\"a}-Herttuala and Stephen R. Wedge and Juliane M. J{\"u}rgensmeier and Kari Alitalo},
  journal={Cancer research},
  year={2008},
  volume={68 12},
  pages={4754-62}
}
Solid tumors express a range of factors required to sustain their growth and promote their dissemination. Among these are vascular endothelial growth factor-A (VEGF-A), the key angiogenic stimulant, and VEGF-C, a primary mediator of lymphangiogenesis. Small molecule tyrosine kinase inhibitors offer the potential to inhibit more than one kinase and impede tumor growth by multiple mechanisms. However, their potency toward individual targets can vary. Cediranib (RECENTIN; AZD2171) is an inhibitor… CONTINUE READING
50 Citations
52 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 50 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 52 references

Intrinsic versus microenvironmental regulation of lymphatic Cediranib Inhibits Lymphangiogenesis www.aacrjournals.org

  • T Veikkola, M Lohela, K Ikenberg
  • Cancer Res
  • 2008
Highly Influential
11 Excerpts

Similar Papers

Loading similar papers…